Literature DB >> 14744887

Selenium's effects on MMP-2 and TIMP-1 secretion by human trabecular meshwork cells.

Shannon M Conley1, Roberta L Bruhn, Parham V Morgan, W Daniel Stamer.   

Abstract

PURPOSE: Because of the observed increase in incidence of glaucoma among some individuals taking selenium as a dietary supplement, the present study was undertaken to investigate mechanisms of selenium-induced changes in homeostasis of human trabecular meshwork (HTM) cells. Specifically, the impact of selenium on matrix metalloproteinases (MMPs), their inhibitors (tissue inhibitors of metalloproteinases; TIMPs), and the second messengers that regulate MMP expression was investigated in an HTM cell culture model.
METHODS: HTM cell cultures were treated with an organic selenium compound (methyl seleninic acid), and changes in secretion and activity of MMPs and TIMPs were analyzed by Western blot and zymography. Changes in extracellular-signal-related kinases 1 and 2 (ERK1/2) and phospho-ERK1/2 levels were monitored by Western blot analysis of whole-cell lysates prepared from selenium-treated cells. Photographs of cultures over time were used to document selenium-induced changes in cell morphology.
RESULTS: Treatment of HTM cells with selenium for 24 hours at doses ranging from 1 to 10 micro M caused a dose-dependent decrease in the secretion of MMP-2 and TIMP-1. Treatment for 6 hours revealed a significant decrease in MMP-2 and TIMP-1 at the highest dose. MMP-1, -3, and -9 and TIMP-2 were either not detected or their secretion was not consistently influenced by selenium treatment. Selenium treatment caused a significant decrease in ERK1/2 phosphorylation, but no change in overall ERK protein levels. Selenium treatment resulted in dose-dependent, reversible changes in HTM cell-matrix associations.
CONCLUSIONS: Selenium-induced changes in MMP-2/TIMP-1 secretion may alter the balance of extracellular matrix turnover in the conventional outflow pathway and cause an increase in intraocular pressure that eventually leads to glaucoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744887     DOI: 10.1167/iovs.03-0767

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

Review 1.  Rare adipose disorders (RADs) masquerading as obesity.

Authors:  Karen L Herbst
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

2.  Bioengineered glaucomatous 3D human trabecular meshwork as an in vitro disease model.

Authors:  Karen Y Torrejon; Ellen L Papke; Justin R Halman; Judith Stolwijk; Cula N Dautriche; Magnus Bergkvist; John Danias; Susan T Sharfstein; Yubing Xie
Journal:  Biotechnol Bioeng       Date:  2015-12-30       Impact factor: 4.530

Review 3.  The many faces of the trabecular meshwork cell.

Authors:  W Daniel Stamer; Abbot F Clark
Journal:  Exp Eye Res       Date:  2016-07-19       Impact factor: 3.467

Review 4.  Friend or foe? The current epidemiologic evidence on selenium and human cancer risk.

Authors:  Marco Vinceti; Catherine M Crespi; Carlotta Malagoli; Cinzia Del Giovane; Vittorio Krogh
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2013       Impact factor: 3.781

5.  Mesenchymal stem cell-derived exosomes protect trabecular meshwork from oxidative stress.

Authors:  Ying-Chao Li; Juan Zheng; Xi-Zi Wang; Xin Wang; Wen-Jing Liu; Jian-Lu Gao
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.